• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Modified GRADE profiles for included economic studies (to be presented alongside clinical GRADE tables)

StudyPopulationComparatorsCostsEffectsIncr costsIncr effectsICERUncertaintyApplicabilityLimitations
Renehan 2004Patients treated for colorectal cancerConventional follow up (based on 5 trials)£22795.69 life years lostReferenceVarious scenarios were run assuming different cost, effect and discount rate assumptions. For the analysis based on 5 trials, the ICER ranged from £3,285/LYG to £10,757/LYG.Directly applicableMinor limitations
Intensive follow up (based on 5 trials)£47584.97 life years lost£24790.73 life years gained£3402 / LYG
Comments: Incremental health outcomes were measured in terms of life years gained. There is some uncertainty about the impact that quality adjusting survival would have on the ICER, but this is unlikely to change the conclusion of the study.
Macafee 2008Patients who have undergone resection for colorectal cancerStandard follow up (BSG)£53.2 mi559 resectable recurrencesReferenceCost per additional resectable recurrence varied from £16,134 to £25,705.Partially applicablePotentially serious limitations
Intensive follow up (FACS)£68.6 mi1412 resectable recurrences£15.4 mi853 resectable recurrences£18,077 / additional resectable recurrence
Comments: Effects were measured in terms of the number of resectable recurrences identified. The time horizon was limited to 5 years. An appropriate willingness to pay threshold for interpreting the ICER results is not known.

From: 5, Ongoing Care and Support

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.